• Miami Beach



  • Miami Liberty
26 - 27 April 2019 | Hilton Miami Downtown


In keeping with our mission, the co-chairs and organizing committee evaluated alternative locations and determined that Miami was the ideal successor to New York as our symposium location in 2019. With more than 50% of all new cases of diagnosed HIV presenting in the south these past couple of years, and Miami a recognized epicenter, state of the art accessible education for clinicians is more important than ever. Miami also offers easy access for attendees in the US, Caribbean and Europe.

You can expect the same stellar faculty and robust topic agenda that this annual event has offered for almost two decades.

17th Annual CME Symposium

This advanced CME activity will provide participants with state-of-the-art information and practical guidance from internationally recognized experts on progress in managing HIV and viral hepatitis, including drug development and treatment, management of important comorbidities, and drug-drug interactions. The discussions at this meeting will allow clinicians to provide the highest quality of care in a variety of practice settings.

The primary goals of this activity are to increase each attendee’s competence to:

  • Summarize approaches to curing HIV infection, eliminating the viral reservoir, and ending the HIV epidemic
  • Determine optimal approaches for identifying, protecting and treating individuals at greatest risk for HIV infection in 2019 and beyond
  • Identify the optimal antiretroviral management options for patients with HIV and newer therapies in development
  • Describe technological advances in infectious diseases diagnostics
  • Examine challenges to and steps necessary for ending the opiate epidemic
  • Detail current and developing treatment options for managing patients with viral hepatitis and its complications, including in special populations (pregnancy, HCV genotype 3, HIV/HCV coinfection, HBV/HCV coinfection)
  • Clarify uncertainties in the optimal management of viral hepatitis
  • Demonstrate optimal management strategies for patients with liver disease other than viral hepatitis, including nonalcoholic liver disease and drug-induced liver injury

Target Audience

The curriculum offered at this activity is designed to meet the needs of Infectious Disease Physicians, Hepatologists, Gastroenterologists, Family Physicians, Nurse Practitioners, Physician Assistants, Nurses, Pharmacists, and others involved in frontline HIV and Hepatitis patient care and treatment.

This CME activity is made possible, in part, by educational grants provided or pledged by:

 Gilead Sciences
 ViiV Healthcare
 AbbVie, Merck US Human Health
 Janssen Therapeutics, Roche Diagnostics